Patents by Inventor Mark M. Foreman
Mark M. Foreman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 6770638Abstract: Pharmaceutical composite compositions comprising tetrahydroindolones linked to arylpiperazines and derivatives thereof are disclosed. Specifically, composite compositions useful in treating anti-psychotic disorders are disclosed. The composite compositions disclosed herein can effectively ameliorate symptoms and treat psychotic disorders without causing a decrease in cognitive function. Generally, the composite compounds consist of two moieties, moiety A and B in which a tetrahydroindolone comprises a moiety A linked through a linker L to a moiety B, where B is an arylpiperazinyl moiety. The composite compound provides anti-psychotic actively by interaction with GABA, seratoninne and dopamine receptors. The composite molecules with the combined activities will provide treat psychiatric and neurological diseases without cognitive impairment.Type: GrantFiled: July 30, 2002Date of Patent: August 3, 2004Assignee: Spectrum Pharmaceuticals, Inc.Inventors: David B. Fick, Mark M. Foreman, Alvin J. Glasky, David R. Helton
-
Patent number: 6759427Abstract: A tetrahydroindolone derivative or analogue comprises a 9-atom bicyclic moiety, moiety A, linked through a linker L to a moiety B, where B is a carboxylic acid, a carboxylic acid ester, or a moiety of the structure N(Y1)-D, where Y1 can be one of a variety of substituents, including hydrogen or alkyl, and D is a moiety that enhances the pharmacological effects, promotes absorption or blood-brain barrier penetration of the derivative or analogue. The moiety A has a six-membered ring fused to a five-membered ring. The moiety A can have one, two, or three nitrogen atoms in the five membered ring. The moiety A can be a tetrahydroindolone moiety. The moiety B can be one of a variety of moieties, including moieties having nootropic activity or other biological or physiological activity.Type: GrantFiled: April 20, 2001Date of Patent: July 6, 2004Assignee: Spectrum Pharmaceuticals, Inc.Inventors: David B. Fick, Mark M. Foreman, Alvin J. Glasky
-
Publication number: 20040116453Abstract: A pyrimidine derivative or analogue comprises an amino-substituted six-membered heterocyclic moiety, moiety A, linked through a linker L to a moiety B, where B is a carboxylic acid, a carboxylic acid ester, or a moiety of the structure N(Y1)-D, where Y1 can be one of a variety of substituents, including hydrogen or alkyl, and D is a moiety that enhances the pharmacological effects, promotes absorption, or promotes blood-brain barrier penetration of the derivative or analogue. The moiety A can have two or three nitrogen atoms in the ring; typically, the moiety A is a pyrimidine moiety, with two nitrogen atoms in the ring. The moiety B can be one of a variety of moieties, including moieties having nootropic activity or other biological or physiological activity.Type: ApplicationFiled: August 25, 2003Publication date: June 17, 2004Inventors: David B. Fick, Mark M. Foreman, Alvin J. Glasky
-
Patent number: 6630478Abstract: A method of treating drug-induced peripheral neuropathy comprising administering to a patient with drug-induced peripheral neuropathy an effective quantity of N-4-carboxaphenyl-3-(6-oxohydropurin-9-yl)propananide AIT-082, is disclosed. Peripheral nerve sprouting can be induced through the action of a neurotrophic factor such as nerve growth factor (NGF) without the occurrence of hyperalgesia. The peripheral nerve sprouting can be nociceptive nerve sprouting. The drug-induced peripheral neuropathy is associated with the administration of oncolytic drugs, such as a vinca alkaloid, cisplatin, paclitaxel, suramin, altretamine, carboplatin, chlorambucil, cytarabine, dacarbazine, docetaxel, etoposide, fludarabine, ifosfamide with mesna, tamoxifen, teniposide, or thioguanine.Type: GrantFiled: July 6, 2001Date of Patent: October 7, 2003Assignee: NeoTherapeutics, Inc.Inventors: Jack Diamond, Alvin J. Glasky, Mark M. Foreman
-
Publication number: 20030114463Abstract: Pharmaceutical composite compositions comprising tetrahydroindolones linked to arylpiperazines and derivatives thereof are disclosed. Specifically, composite compositions useful in treating anti-psychotic disorders are disclosed. The composite compositions disclosed herein can effectively ameliorate symptoms and treat psychotic disorders without causing a decrease in cognitive function. Generally, the composite compounds consist of two moieties, moiety A and B in which a tetrahydroindolone comprises a moiety A linked through a linker L to a moiety B, where B is an arylpiperazinyl moiety. The composite compound provides anti-psychotic actively by interaction with GABA, seratoninne and dopamine receptors. The composite molecules with the combined activities will provide treat psychiatric and neurological diseases without cognitive impairment.Type: ApplicationFiled: July 30, 2002Publication date: June 19, 2003Inventors: David B. Fick, Mark M. Foreman, Alvin J. Glasky, David R. Helton
-
Publication number: 20030055249Abstract: A pyrimidine derivative or analogue comprises an amino-substituted six-membered heterocyclic moiety, moiety A, linked through a linker L to a moiety B, where B is a carboxylic acid, a carboxylic acid ester, or a moiety of the structure N(Y1)-D, where Y1 can be one of a variety of substituents, including hydrogen or alkyl, and D is a moiety that enhances the pharmacological effects, promotes absorption, or promotes blood-brain barrier penetration of the derivative or analogue. The moiety A can have two or three nitrogen atoms in the ring; typically, the moiety A is a pyrimidine moiety, with two nitrogen atoms in the ring. The moiety B can be one of a variety of moieties, including moieties having nootropic activity or other biological or physiological activity.Type: ApplicationFiled: July 17, 2001Publication date: March 20, 2003Inventors: David B. Fick, Mark M. Foreman, Alvin J. Glasky
-
Publication number: 20020198218Abstract: A tetrahydroindolone derivative or analogue comprises a 9-atom bicyclic moiety, moiety A, linked through a linker L to a moiety B, where B is a carboxylic acid, a carboxylic acid ester, or a moiety of the structure N(Y1)-D, where Y1 can be one of a variety of substituents, including hydrogen or alkyl, and D is a moiety that enhances the pharmacological effects, promotes absorption or blood-brain barrier penetration of the derivative or analogue. The moiety A has a six-membered ring fused to a five-membered ring. The moiety A can have one, two, or three nitrogen atoms in the five membered ring. The moiety A can be a tetrahydroindolone moiety. The moiety B can be one of a variety of moieties, including moieties having nootropic activity or other biological or physiological activity.Type: ApplicationFiled: April 20, 2001Publication date: December 26, 2002Inventors: David B. Fick, Mark M. Foreman, Alvin J. Glasky
-
Publication number: 20020156277Abstract: A purine derivative or analogue comprises a 9-atom bicyclic moiety, moiety A, linked through a linker L to a moiety B, where B is a carboxylic acid, a carboxylic acid ester, or a moiety of the structure N(Y1)—D, where Y1 can be one of a variety of substituents, including hydrogen or alkyl, and D is a moiety that enhances the pharmacological effects, promotes absorption or blood-brain barrier penetration of the derivative or analogue. The moiety A has a six-membered ring fused to a five-membered ring. The moiety A can have one, two, or three nitrogen atoms in the five membered ring and has two nitrogen atoms in the six-membered ring. The moiety A can be a purine moiety. The moiety B can be one of a variety of moieties, including moieties having nootropic activity or other biological or physiological activity.Type: ApplicationFiled: April 20, 2001Publication date: October 24, 2002Inventors: David B. Fick, Mark M. Foreman, Alvin J. Glasky
-
Publication number: 20020061899Abstract: A method of treating drug-induced peripheral neuropathy comprises administering to a patient with drug-induced peripheral neuropathy an effective quantity of a purine derivative or analogue, a tetrahydroindolone derivative or analogue, or a pyrimidine derivative or analogue. If the compound is a purine derivative, the purine moiety can be guanine or hypoxanthine. The compound can induce peripheral nerve sprouting through the action of a neurotrophic factor such as nerve growth factor (NGF) without the occurrence of hyperalgesia. The peripheral nerve sprouting can be nociceptive nerve sprouting. The drug-induced peripheral neuropathy can be drug-induced peripheral neuropathy associated with the administration of oncolytic drugs, such as a vinca alkaloid, cisplatin, paclitaxel, suramin, altretamine, carboplatin, chlorambucil, cytarabine, dacarbazine, docetaxel, etoposide, fludarabine, ifosfamide with mesna, tamoxifen, teniposide, or thioguanine.Type: ApplicationFiled: July 6, 2001Publication date: May 23, 2002Inventors: Jack Diamond, Alvin J. Glasky, Mark M. Foreman
-
Patent number: 5703112Abstract: The present invention provides methods of preventing emesis and treating sexual dysfunction in mammals utilizing certain tetrahydrobenz?cd!indoles. The invention further provides pharmaceutical formulations suitable for use in such methods.Type: GrantFiled: November 17, 1995Date of Patent: December 30, 1997Assignee: Eli Lilly and CompanyInventors: Mark M. Foreman, J. David Leander
-
Patent number: 5462962Abstract: This invention provides 6-substituted-4-(amino or substituted amino)tetrahydrobenz[c,d]indole serotonin agonists useful in treating a variety of conditions associated with serotonin function.Type: GrantFiled: December 15, 1992Date of Patent: October 31, 1995Assignee: Eli Lilly and CompanyInventors: Michael E. Flaugh, Mark M. Foreman
-
Patent number: 5441985Abstract: This invention provides a method of treating lower urinary tract disorders in mammals employing compounds which inhibit norepinephrine reuptake and having negligible anticholinergic effect.Type: GrantFiled: May 13, 1993Date of Patent: August 15, 1995Assignee: Eli Lilly and CompanyInventor: Mark M. Foreman
-
Patent number: 5204340Abstract: This invention provides 6-substituted-4-(amino or substituted amino)tetrahydrobenz[c,d]indole serotonin agonists useful in treating a variety of conditions associated with serotonin function.Type: GrantFiled: February 26, 1990Date of Patent: April 20, 1993Assignee: Eli Lilly and CompanyInventors: Michael E. Flaugh, Mark M. Foreman
-
Patent number: 4931447Abstract: This invention provides (8.beta.)-N-cycloalkyl-1-alkyl-6-(substituted) ergoline-8-carboxamides useful for blocking 5HT.sub.2 receptors in mammals having an excess of serotonin centrally or peripherally. The invention also provides methods for treating hypertension, migraine, vasospasm, thrombosis, ischemia, depression, anxiety, sleep disorders and appetite disorders with a compound of the invention.Type: GrantFiled: August 14, 1989Date of Patent: June 5, 1990Assignee: Eli Lilly and CompanyInventors: Mark M. Foreman, William L. Garbrecht, Gifford P. Marzoni, Kathleen R. Whitten
-
Patent number: 4528290Abstract: Dopamine D-1 agonists, trans-(+)tautomers of the formula ##STR1##Type: GrantFiled: January 30, 1984Date of Patent: July 9, 1985Assignee: Eli Lilly and CompanyInventors: David T. Wong, Mark M. Foreman
-
Patent number: 4521421Abstract: Sexual dysfunction in mammals is treated with a trans-(.+-.)- or trans-(-)-2-amino-4-permissibly-substituted-6-loweralkyl or allyl octahydropyrimido[4,5-g]quinoline or a pharmaceutically-acceptable acid addition salt thereof.Type: GrantFiled: September 26, 1983Date of Patent: June 4, 1985Assignee: Eli Lilly and CompanyInventor: Mark M. Foreman